Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haw ParHAWPF 93 Return-on-Tangible-Asset is 5.62% as of Dec. 2025, which is 6% above its 10-year median of 5.28. GuruFocus rates HAWPF with a GF Score™ of 93/100 and a GF Value™ of $8.51. The stock has 8 warning signs investors should review. Among 1,009 Drug Manufacturers companies, Haw Par ranks better than 64.42% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Haw Par's annualizedNet Income for the quarter that ended in Dec. 2025 was $188.0 Mil. Haw Par's average total tangible assets for the quarter that ended in Dec. 2025 was $3,343.3 Mil. Therefore, Haw Par's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 5.62%.
The historical rank and industry rank for Haw Par's Return-on-Tangible-Asset or its related term are showing as below:
HAWPF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.55 Med: 5.28 Max: 6.19
Current: 6.19
During the past 13 years, Haw Par's highest Return-on-Tangible-Asset was 6.19%. The lowest was 3.55%. And the median was 5.28%.
HAWPF's Return-on-Tangible-Asset is ranked better than 64.42% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs HAWPF: 6.19
Haw Par (OTCPK:HAWPF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Haw Par Return-on-Tangible-Asset Related Terms
Haw Par Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Haw Par's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAWPF vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Haw Par's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Haw Par's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 5.62% mean?
Haw Par (HAWPF) has a Return-on-Tangible-Asset of 5.62% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Haw Par and its competitors. This is near median its historical median of 5.28. Over the past decade, Haw Par's Return-on-Tangible-Asset has ranged from 3.55 to 6.19. According to the industry distribution chart, Haw Par ranks #359 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 35.6%.
Is Haw Par's Return-on-Tangible-Asset too high?
Haw Par's current Return-on-Tangible-Asset of 5.62% is near median its 10-year median of 5.28. Over the past 10 years, this metric has ranged from a low of 3.55 to a high of 6.19. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Haw Par's value of 5.62% is 78.4% above this industry median. Based on the distribution chart, Haw Par ranks #359 out of 1009 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Haw Par has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #359 out of 1009 companies for Return-on-Tangible-Asset. This puts Haw Par in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.15. Haw Par's value of 5.62% is 78.4% above this benchmark. Historically, Haw Par's own Return-on-Tangible-Asset has ranged from 3.55 to 6.19 over the past decade. While the company's 10-year median is 5.28 vs. the industry median of 3.15, Haw Par has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current Return-on-Tangible-Asset of 5.62% is 78.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current Return-on-Tangible-Asset is 5.62%, which is near median its own 10-year median of 5.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current Return-on-Tangible-Asset of 5.62%. The stock's GF Value™ is $8.51, compared to a current price of $12.00 — trading 41% above its estimated fair value. The current Return-on-Tangible-Asset is 5.62%, which is near median its 10-year median of 5.28 and 78.4% above the Drug Manufacturers industry median of 3.15. Haw Par's overall GF Score™ is 93/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Haw Par (HAWPF), the current Return-on-Tangible-Asset is 5.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.00 is trading 41% above its estimated GF Value™ of $8.51.
Key valuation signals for HAWPF:
Return-on-Tangible-Asset: 5.62% (near median its 10-year median of 5.28)
GF Value™: $8.51 vs. price of $12.00 (41% above fair value)
Industry Position: 78.4% above the Drug Manufacturers median (#359 of 1009)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
93GF Score
Get the complete analysis for HAWPF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
